Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges
Targeted therapies and immunotherapies have improved the clinical outcome of cancer patients; however, the efficacy of treatment remains frequently limited due to low predictability of response and development of drug resistance. Therefore, novel therapeutic strategies for various cancer types are n...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2024-11, Vol.25 (23), p.12804 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 23 |
| container_start_page | 12804 |
| container_title | International journal of molecular sciences |
| container_volume | 25 |
| creator | Gajos-Michniewicz, Anna Czyz, Malgorzata |
| description | Targeted therapies and immunotherapies have improved the clinical outcome of cancer patients; however, the efficacy of treatment remains frequently limited due to low predictability of response and development of drug resistance. Therefore, novel therapeutic strategies for various cancer types are needed. Current research emphasizes the potential therapeutic value of targeting WNT/β-catenin dependent signaling that is deregulated in various cancer types. Targeting the WNT/β-catenin signaling pathway with diverse synthetic and natural agents is the subject of a number of preclinical studies and clinical trials for cancer patients. The usage of nature-derived agents is attributed to their health benefits, reduced toxicity and side effects compared to synthetic agents. The review summarizes preclinical studies and ongoing clinical trials that aim to target components of the WNT/β-catenin pathway across a diverse spectrum of cancer types, highlighting their potential to improve cancer treatment. |
| doi_str_mv | 10.3390/ijms252312804 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3144194918</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146911554</sourcerecordid><originalsourceid>FETCH-LOGICAL-c246t-e91dff116cb20e8285f5887c6e5b4a3750f076b0d926bd250a04d49a3c980d943</originalsourceid><addsrcrecordid>eNpdkbtOwzAUhi0EolAYWZElFpZQX9OYrYq4SeUiUcQYOYlTUiV28WVg4aF4EJ4JFwoCJv8--s4nHf0AHGB0QqlAo3bRO8IJxSRDbAPsYEZIglA63vyVB2DXuQVChBIutsGAijRjHNMd8Dp7UlYuVfBtBe-MV9q3soOmgTfSBxtjbvqlCbp20Bt4berQSa_g481s9P6W5DHrVsP7dq5l1-o5jJ9c6krZU5gHa6MP3vvVRlROrIdS1zB_kl2n9Fy5PbDVyM6p_fU7BA_nZ7P8MpneXlzlk2lSEZb6RAlcNw3GaVUSpDKS8YZn2bhKFS-ZpGOOGjROS1QLkpY14UgiVjMhaSWyOGR0CI6_vEtrnoNyvuhbV6muk1qZ4AqKWSow5nyFHv1DFybYeN0nxbBgAmeRSr6oyhrnrGqKpW17aV8KjIpVMcWfYiJ_uLaGslf1D_3dBP0A5eCJPg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3144194918</pqid></control><display><type>article</type><title>Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges</title><source>MEDLINE</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Gajos-Michniewicz, Anna ; Czyz, Malgorzata</creator><creatorcontrib>Gajos-Michniewicz, Anna ; Czyz, Malgorzata</creatorcontrib><description>Targeted therapies and immunotherapies have improved the clinical outcome of cancer patients; however, the efficacy of treatment remains frequently limited due to low predictability of response and development of drug resistance. Therefore, novel therapeutic strategies for various cancer types are needed. Current research emphasizes the potential therapeutic value of targeting WNT/β-catenin dependent signaling that is deregulated in various cancer types. Targeting the WNT/β-catenin signaling pathway with diverse synthetic and natural agents is the subject of a number of preclinical studies and clinical trials for cancer patients. The usage of nature-derived agents is attributed to their health benefits, reduced toxicity and side effects compared to synthetic agents. The review summarizes preclinical studies and ongoing clinical trials that aim to target components of the WNT/β-catenin pathway across a diverse spectrum of cancer types, highlighting their potential to improve cancer treatment.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms252312804</identifier><identifier>PMID: 39684513</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; beta Catenin - metabolism ; Biological Products - pharmacology ; Biological Products - therapeutic use ; Cancer therapies ; Colorectal cancer ; Genes ; Glycoproteins ; Growth factors ; Humans ; Immunotherapy ; Kinases ; Ligands ; Liver cancer ; Melanoma ; Metastasis ; Molecular Targeted Therapy - methods ; Mutation ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Ovarian cancer ; Plasma ; Proteins ; Wnt Signaling Pathway - drug effects</subject><ispartof>International journal of molecular sciences, 2024-11, Vol.25 (23), p.12804</ispartof><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c246t-e91dff116cb20e8285f5887c6e5b4a3750f076b0d926bd250a04d49a3c980d943</cites><orcidid>0000-0002-8279-4742 ; 0000-0002-6159-4194</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39684513$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gajos-Michniewicz, Anna</creatorcontrib><creatorcontrib>Czyz, Malgorzata</creatorcontrib><title>Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Targeted therapies and immunotherapies have improved the clinical outcome of cancer patients; however, the efficacy of treatment remains frequently limited due to low predictability of response and development of drug resistance. Therefore, novel therapeutic strategies for various cancer types are needed. Current research emphasizes the potential therapeutic value of targeting WNT/β-catenin dependent signaling that is deregulated in various cancer types. Targeting the WNT/β-catenin signaling pathway with diverse synthetic and natural agents is the subject of a number of preclinical studies and clinical trials for cancer patients. The usage of nature-derived agents is attributed to their health benefits, reduced toxicity and side effects compared to synthetic agents. The review summarizes preclinical studies and ongoing clinical trials that aim to target components of the WNT/β-catenin pathway across a diverse spectrum of cancer types, highlighting their potential to improve cancer treatment.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>beta Catenin - metabolism</subject><subject>Biological Products - pharmacology</subject><subject>Biological Products - therapeutic use</subject><subject>Cancer therapies</subject><subject>Colorectal cancer</subject><subject>Genes</subject><subject>Glycoproteins</subject><subject>Growth factors</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Kinases</subject><subject>Ligands</subject><subject>Liver cancer</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Mutation</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Ovarian cancer</subject><subject>Plasma</subject><subject>Proteins</subject><subject>Wnt Signaling Pathway - drug effects</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkbtOwzAUhi0EolAYWZElFpZQX9OYrYq4SeUiUcQYOYlTUiV28WVg4aF4EJ4JFwoCJv8--s4nHf0AHGB0QqlAo3bRO8IJxSRDbAPsYEZIglA63vyVB2DXuQVChBIutsGAijRjHNMd8Dp7UlYuVfBtBe-MV9q3soOmgTfSBxtjbvqlCbp20Bt4berQSa_g481s9P6W5DHrVsP7dq5l1-o5jJ9c6krZU5gHa6MP3vvVRlROrIdS1zB_kl2n9Fy5PbDVyM6p_fU7BA_nZ7P8MpneXlzlk2lSEZb6RAlcNw3GaVUSpDKS8YZn2bhKFS-ZpGOOGjROS1QLkpY14UgiVjMhaSWyOGR0CI6_vEtrnoNyvuhbV6muk1qZ4AqKWSow5nyFHv1DFybYeN0nxbBgAmeRSr6oyhrnrGqKpW17aV8KjIpVMcWfYiJ_uLaGslf1D_3dBP0A5eCJPg</recordid><startdate>20241128</startdate><enddate>20241128</enddate><creator>Gajos-Michniewicz, Anna</creator><creator>Czyz, Malgorzata</creator><general>MDPI AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8279-4742</orcidid><orcidid>https://orcid.org/0000-0002-6159-4194</orcidid></search><sort><creationdate>20241128</creationdate><title>Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges</title><author>Gajos-Michniewicz, Anna ; Czyz, Malgorzata</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c246t-e91dff116cb20e8285f5887c6e5b4a3750f076b0d926bd250a04d49a3c980d943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>beta Catenin - metabolism</topic><topic>Biological Products - pharmacology</topic><topic>Biological Products - therapeutic use</topic><topic>Cancer therapies</topic><topic>Colorectal cancer</topic><topic>Genes</topic><topic>Glycoproteins</topic><topic>Growth factors</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Kinases</topic><topic>Ligands</topic><topic>Liver cancer</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Mutation</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Ovarian cancer</topic><topic>Plasma</topic><topic>Proteins</topic><topic>Wnt Signaling Pathway - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gajos-Michniewicz, Anna</creatorcontrib><creatorcontrib>Czyz, Malgorzata</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gajos-Michniewicz, Anna</au><au>Czyz, Malgorzata</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2024-11-28</date><risdate>2024</risdate><volume>25</volume><issue>23</issue><spage>12804</spage><pages>12804-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Targeted therapies and immunotherapies have improved the clinical outcome of cancer patients; however, the efficacy of treatment remains frequently limited due to low predictability of response and development of drug resistance. Therefore, novel therapeutic strategies for various cancer types are needed. Current research emphasizes the potential therapeutic value of targeting WNT/β-catenin dependent signaling that is deregulated in various cancer types. Targeting the WNT/β-catenin signaling pathway with diverse synthetic and natural agents is the subject of a number of preclinical studies and clinical trials for cancer patients. The usage of nature-derived agents is attributed to their health benefits, reduced toxicity and side effects compared to synthetic agents. The review summarizes preclinical studies and ongoing clinical trials that aim to target components of the WNT/β-catenin pathway across a diverse spectrum of cancer types, highlighting their potential to improve cancer treatment.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39684513</pmid><doi>10.3390/ijms252312804</doi><orcidid>https://orcid.org/0000-0002-8279-4742</orcidid><orcidid>https://orcid.org/0000-0002-6159-4194</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2024-11, Vol.25 (23), p.12804 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_proquest_journals_3144194918 |
| source | MEDLINE; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use beta Catenin - metabolism Biological Products - pharmacology Biological Products - therapeutic use Cancer therapies Colorectal cancer Genes Glycoproteins Growth factors Humans Immunotherapy Kinases Ligands Liver cancer Melanoma Metastasis Molecular Targeted Therapy - methods Mutation Neoplasms - drug therapy Neoplasms - metabolism Ovarian cancer Plasma Proteins Wnt Signaling Pathway - drug effects |
| title | Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T22%3A31%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20Potential%20of%20Natural%20Compounds%20to%20Modulate%20WNT/%CE%B2-Catenin%20Signaling%20in%20Cancer:%20Current%20State%20of%20Art%20and%20Challenges&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Gajos-Michniewicz,%20Anna&rft.date=2024-11-28&rft.volume=25&rft.issue=23&rft.spage=12804&rft.pages=12804-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms252312804&rft_dat=%3Cproquest_cross%3E3146911554%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3144194918&rft_id=info:pmid/39684513&rfr_iscdi=true |